Overview

A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)

Status:
Completed
Trial end date:
2017-12-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism in children with all levels of fecal chymotrypsin.
Phase:
Phase 3
Details
Lead Sponsor:
Curemark